| Followers | 200 |
| Posts | 25596 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Saturday, September 25, 2021 1:59:41 PM
It is NWBO’s factory. Not Advent’s factory. Advent is a CDMO, is the operations manager, and is doing all of the work on the client’s (NWBO’s) site. Because the volume for compassionate use is going to be low, and because to get certified they need to have a certain level of resources online always, regardless of volume, and because this certification will also cover commercial use of the facilities, the cost is very high to get to this stage and maintain it the factory in pristine condition until it is turned on for fully approved DCVax commercial production. It can either all sit not being used but ready, or NWBO can allow their contracted CDMO, with inducements, to bear some of that cost in exchange for use of parts of the factory that are not in use and will not be during the period that production might be facilitated for other companies. The companies have a contractual arrangement in place, and they have future intent to find ways to keep the factory ready. The arrangement has been described but likely is not fully fleshed out because the factory has not yet been certified and has only been built out this year in anticipation of certification. Compensation can come in many forms. Not having to maintain the cost of all employees hired to maintain the site ir to do production could be a form of compensation. Once the factory is completed, depending on many other factors, Advent would still need customers who might use the excess space and they’d need to win those production contracts. Companies contracting with them might only be project by project and that might be a disadvantage for them. They will have to see.
So it’s basically hypothetical until it becomes a reality, and at such time, they need to get the permission of NWBO, via their contract and sub-contract arrangement and no doubt those arrangements will each be negotiated at the time they are relevant, on terms that are commercially realistic at that time.
So it’s basically hypothetical until it becomes a reality, and at such time, they need to get the permission of NWBO, via their contract and sub-contract arrangement and no doubt those arrangements will each be negotiated at the time they are relevant, on terms that are commercially realistic at that time.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
